tiprankstipranks
Trending News
More News >
CombiGene AB (DE:COJ0)
:COJ0
Advertisement

CombiGene AB (COJ0) Price & Analysis

Compare
0 Followers

COJ0 Stock Chart & Stats


COJ0 FAQ

What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was €0.08 and its highest was €0.22 in the past 12 months.
    What is CombiGene AB’s market cap?
    CombiGene AB’s market cap is €4.48M.
      When is CombiGene AB’s upcoming earnings report date?
      CombiGene AB’s upcoming earnings report date is Nov 07, 2025 which is in 61 days.
        How were CombiGene AB’s earnings last quarter?
        CombiGene AB released its earnings results on Aug 22, 2025. The company reported -€0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.056.
          Is CombiGene AB overvalued?
          According to Wall Street analysts CombiGene AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CombiGene AB pay dividends?
            CombiGene AB does not currently pay dividends.
            What is CombiGene AB’s EPS estimate?
            CombiGene AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does CombiGene AB have?
            CombiGene AB has 19,801,197 shares outstanding.
              What happened to CombiGene AB’s price movement after its last earnings report?
              CombiGene AB reported an EPS of -€0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of CombiGene AB?
                Currently, no hedge funds are holding shares in DE:COJ0

                Company Description

                CombiGene AB

                CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

                CombiGene AB (COJ0) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                2cureX AB
                Stayble Therapeutics AB
                LIDDS AB
                ExpreS2ion Biotech Holding AB
                Sprint Bioscience AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis